Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylcholine in atopic eczema patients and healthy controls.
We analysed vasoreactions and sensations of atopic eczema (AE) patients and healthy controls after intracutaneous (i.c.) injection of vasoactive intestinal polypeptide (VIP) and acetylcholine (ACh). Blood flow was measured by laser Doppler flowmetry (LDF). Plasma extravasation and flare size were evaluated planimetrically, and sensations were recorded using visual analog scales. Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated. We administered VIP separately at concentrations of 1.5 x 10(-7), 1.5 x 10(-6) and 1.5 x 10(-5) M and in combination with ACh (5.5 x 10(-6) M) into the volar forearm of the subjects. Both substances led to an increase in LDF measurements and induced a wheal and flare reaction. Blood flow was elevated as a function of dose after a single VIP application in all groups. Compared with healthy controls, a significant increase in blood flow was measured after combined VIP and ACh administration in AE patients suffering from acute AE, whereas flare area and plasma extravasation were significantly reduced after single VIP and combined VIP and ACh injections, respectively. In all groups, VIP induced dose-dependent pruritus. Compared with a control stimulus (0.9% sodium chloride and ACh), combined injections of VIP and ACh had no additional effect on the magnitude of the sensation. In AE patients, the intensity was similar to that experienced by the control subjects, but the quality of sensation was different: ACh induced pain in the control subjects, pruritus in AE patients, and a mixture of pain and itching in AE patients showing no symptoms. Our results suggest that VIP- and ACh-induced skin reactions and the quality of the sensations depend on the activity of the atopic eczema. Confirming our former studies, AE patients develop a different quality of sensation after ACh administration and also after administration of VIP combined with ACh. Therefore, we suggest that ACh might be involved in the pathomechanisms of pruritus in AE.
Rukwied
R
R
Department of Dermatology, University of Erlangen-Nürnberg, Germany.
Heyer
G
G
D000109:Acetylcholine / Q000008:administration & dosage / Q000494:pharmacology*; D000328:Adult; D003876:Dermatitis, Atopic / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology; D007271:Injections, Intradermal; D017078:Laser-Doppler Flowmetry; D008297:Male; D011537:Pruritus / Q000139:chemically induced; D012039:Regional Blood Flow / Q000187:drug effects; D012720:Severity of Illness Index; D012867:Skin / Q000098:blood supply; D012871:Skin Diseases / Q000139:chemically induced* / Q000503:physiopathology*; D012882:Skin Tests; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000494:pharmacology
D004338:Drug Combinations; D014660:Vasoactive Intestinal Peptide; D000109:Acetylcholine